Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

European Research Council grant · Finished

CHEMCELL Chemical Engineering of Natural Killer Cells for Cancer Immunotherapy

Coordinator
Ustav Organicke Chemie a Biochemie, Av Cr, V.v.i., Czechia
Runs
1 September 2022 to 29 February 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101081736

What the project is doing

In the project's own words, from its summary on CORDIS.

Our immune system evolved to protect our bodies from different invaders and to fight against infections and diseases. Immune cells use sophisticated ways to detect and destroy abnormal cells, while sparing our own cells. Unluckily, cancer cells often develop sneaky tricks enabling them to evade this protecting machinery and to survive and proliferate. Immunotherapy, an emerging concept of treatment, aims to employ the power of immune system to fight cancer by boosting or reeducation of immune cells.

One of the approaches, the adoptive cell transfer therapy, especially in the form of chimeric antigen receptor (CAR) cells, has shown an unprecedented success in the treatment of certain types of cancer. CAR cells are genetically modified immune cells engineered to recognize and kill cells with specific cancer antigen. Unfortunately, production of genetically modified CARs is problematic, inefficient, time consuming and therefore, associated with high costs.

New approaches enabling production of modified immune cells more effectively, faster and cheaper could therefore change the way the therapy is used. Within this proposal, we will explore the potential of an innovative approach for production of chemically engineered immune cells and their application in immunotherapy. In particular, we will employ our technology based on combination of metabolic engineering and subsequent biocompatible chemical labeling to produce an antibody modified natural killer (NK) cells that we will investigate in cancer killing experiments.

We will perform a side-by-side comparison of our technology with the traditional CAR-NK cells both, in vitro and in vivo, to evaluate the pros and cons of both approaches. Finally, in collaboration with our Tech Transfer Office, we will present the technology to potential stakeholders to bring it to the next step in the form of patent licensing or eventually, develop the technology further within spin-out company.

Topics

Who is involved

OrganisationCityCountryRole
Ustav Organicke Chemie a Biochemie, Av Cr, V.v.i.Praha 6CzechiaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI